NCT04601402: GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

NCT04601402
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase of the study; Patients must have progressed on at least two lines of anti-PD-1/L1-based therapy (as monotherapy or in combination)
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases and/or leptomeningeal disease- see trial for details
https://ClinicalTrials.gov/show/NCT04601402

Comments are closed.

Up ↑